8EQ.F CYTEK BIOSCIENCES DL-001
- Market cap
- EUR 667M
- P/E
- -
- P/B
- 2.37x
- ROE
- -15.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8EQ.F undervalued?
Graham numberThe Graham number of CYTEK BIOSCIENCES DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CYTEK BIOSCIENCES DL-001 fundamental analysis
No fundamental analysis for CYTEK BIOSCIENCES DL-001 yet.
CYTEK BIOSCIENCES DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CYTEK BIOSCIENCES DL-001
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagest…
Full company profileCYTEK BIOSCIENCES DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CYTEK BIOSCIENCES DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 128M | 164M | 193M | 200M | 201M | 194M |
| Gross Profit | 79.1M | 101M | 109M | 111M | 104M | 108M |
| Operating Income | 9.16M | -1.80M | -27.8M | -20.5M | -40.4M | -51.0M |
| EBITDA | - | 9.49M | -4.41M | -10.0M | -17.4M | -35.0M |
| Net Income | 3.00M | 2.58M | -12.1M | -6.02M | -66.5M | -49.5M |
| EPS | 0.02 | 0.02 | -0.09 | -0.05 | -0.52 | -0.38 |
| Balance Sheet | ||||||
| Total Assets | 463M | 519M | 494M | 500M | 462M | 446M |
| Total Liabilities | 57.9M | 93.9M | 101M | 104M | 120M | 125M |
| Shareholders' Equity | 405M | 425M | 393M | 396M | 342M | 321M |
| Cash & Short-term Investments | 365M | 297M | 167M | 98.7M | 90.9M | 66.8M |
| Cash Flow | ||||||
| Operating Cash Flow | 4.63M | -12.2M | 5.28M | 25.4M | -4.69M | -7.76M |
| Capital Expenditure | 4.36M | 9.87M | 4.83M | 3.73M | 4.19M | 7.99M |
| Free Cash Flow | 266K | -22.1M | 454K | 21.7M | -8.88M | -15.8M |
| Ratios | ||||||
| ROE | 0.7% | 0.6% | -3.1% | -1.5% | -19.5% | -15.4% |
| ROA | 0.6% | 0.5% | -2.5% | -1.2% | -14.4% | -11.1% |
| Net Profit Margin | 2.3% | 1.6% | -6.3% | -3.0% | -33.0% | -25.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CYTEK BIOSCIENCES DL-001 dividends
CYTEK BIOSCIENCES DL-001 has not paid dividends in the last 5 fiscal years.
Who owns CYTEK BIOSCIENCES DL-001
- Insiders 8.42%
- Institutions 61.92%
- Public & others 29.66%
- Shares outstanding 131M
- Free float 106M
CYTEK BIOSCIENCES DL-001 company profile
- Company name
- CYTEK BIOSCIENCES DL-001
- Ticker
- 8EQ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 703
- Fiscal year end
- December
- Address
- 47215 Lakeview Blvd, Fremont, CA, United States, 94538-6407
- Phone
- 877 922 9835
- Website
- cytekbio.com
About CYTEK BIOSCIENCES DL-001
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
CYTEK BIOSCIENCES DL-001 management
6- Dr. Wenbin Jiang Ph.D.President, CEO & Chairman of the Board · born 1964
- Mr. William D. McCombeChief Financial Officer · born 1958
- Dr. Ming Yan Ph.D.CTO & Director · born 1963
- Mr. Paul D. GoodsonHead of Investor Relations
- Mr. Ilan B. FeuchtwangChief Legal Officer
- Mr. Patrik Sebastian JeanmonodHead of Corporate Development Analytics · born 1966